A pioneer in the quality control initiatives for SARS-CoV2, Controllab – the country’s largest proficiency provider, launched in February the Proficiency Testing for Research on Neutralizing Antibodies: Coronavirus (SARS-CoV2). Interested parties will receive the pilot round at no cost.
The news of the beginning of the vaccination to face Covid-19 was celebrated worldwide. However, production and logistics restrictions are some of the challenges for the population to be widely vaccinated.
Amid the uncertainties in the speed of access to vaccine, the knowledge about the period they generate immunity to the disease and the wide dissemination of studies on Covid Immunity not to be lasting, the demand for the Neutralizing Antibody Research for Covid-19 is growing.
To help the laboratories that offer this test to demonstrate the reliability of their results, next month, Controllab will conduct the pilot round of the Proficiency Testing for Research on Neutralizing Antibodies: Coronavirus (SARS-CoV2).
The program consists of multiple items, in which the evaluation will be made available in an individual results report with a concept and another report with a general profile of the performance of the reported kits. The profile contributes to assertive decisions about the systems adopted in the routine.
The pilot round will be sent with five items from different donors and was structured according to the guidelines of ISO/IEC 17043. More details on the benefits that the laboratory will obtain from participating in this Proficiency Testing, can be obtained on the service page.
Those interested in participating in the pilot round, which will be sent free of charge on February 8, can indicate their participation in this link until the end of January.
